Canadian Pharmacists Association
Canadian Pharmacists Association

Ozempic and other GLP-1 agonists supply

January 2024 update: 

  • As of January 17, 2024, the Ozempic® 1mg status has been updated to resolved.
  • To support the Ozempic® low dose supply, Health Canada expedited the approval of a new 3 mL Ozempic® (DIN: 02540258) dose pen. The low dose supply is being transitioned from the previous Ozempic® 0.25mg/0.5mg – 1.5mL to the new Ozempic® 0.25mg/0.5mg – 3mL format.
  • Novo Nordisk continues to recommend a 30-day supply for all formats to ensure the supply situation remains stable.

Products impacted

Ozempic

While the supply situation continues to improve and stabilize, Canadians may continue to experience intermittent delays due to continued high global demand.

Ozempic® 1 mg pen (DIN: 02471469)

Updated to resolved on January 17, 2024

More info: View shortage report.

Ozempic® 0.25/0.5 mg pen – 1.5mL(DIN: 02471477)

Shortage due to demand increase.

More info: View shortage report.

Note: Health Canada expedited the approval of a new 3 mL Ozempic® low dose (0.25mg/0.5mg) pen to stabilize Ozempic® low dose (0.25mg/0.5mg) supply. The shortage of the Ozempic® (0.25mg/0.5mg) pen listed on the Drug Shortages webpage applies only to the previous 1.5mL pen and will be maintained until the transition to the new 3mL pen is complete.

Ozempic® 0.25/0.5 mg – 3mL pen (DIN: 02540258 )


Other products

Eli Lilly Canada Inc, which markets Trulicity (Dulaglutide) and Mounjaro (Tirzepatide), a GIP and GLP-1 receptor agonist, is also experiencing shortages of both drugs in Canada.

Mounjaro® 
Various strengths

Shortage due to demand increase.

More info: View shortage reports

Trulicity®
Various strengths

Shortage due to demand increase.

More info: View shortage reports

 

30-day supply recommendation

Novo Nordisk Canada Inc. and Eli Lilly Canada Inc. are asking pharmacists to limit refill prescriptions for patients to a 30-day supply. Patients are encouraged to contact their pharmacy well in advance of running out of their current supply.

Given the scope of the shortage and the manufacturer recommendations to limit dispensing to a 30-day supply, CPhA continues to advocate on behalf of pharmacists and encourage insurers to enable 30-day supply.

Recommendations for prescribers 

Based on advice from clinical expert groups, Health Canada published the following recommendations for health providers.

  • Do not start new patients on these drugs that are in shortage, unless there are no suitable alternatives and there’s a clinical reason to do so
  • Consider prescribing an alternative drug for patients taking one of these drugs that are in shortage, as a continuous supply can’t be guaranteed 
  • Conserve the existing supply for patients who are stabilized and have no other treatment options

For more information: Recommendations while Ozempic and other GLP-1 agonists are in shortage.

Resources for pharmacy professionals

CPhA has collaborated with medSask on resources to provide guidance for managing this shortage, which includes information about alternative therapies.

Sign up for our mailing list

Interested in helping CPhA combat drug shortages?

Join the Pharmacy Virtual Advisory Team.

Last updated: February 14, 2024